

## **CHROMEDX ENGAGES BIOSENSOR DEVELOPMENT EXPERT** **STEPHEN COZZETTE**

January 26, 2015 – ChroMedX Corp. (the “**Company**”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of Mr. Stephen Cozzette as a consultant on the HemoPalm project focussing on the electrochemical sensor and cartridge development aspects of the project.

“We are very excited to add Stephens’s expertise to the team. Mr. Cozzette is particularly skilful at integrating design controls in an entrepreneurial reality and his background in the area of electrochemical sensor and cartridge development will greatly assist our efforts in producing a market leading technology.”, said Dr. Wayne Maddever, ChroMedX Corp. President & CEO

Mr. Cozzette has 25+ years experience in sensor and cartridge development having played a major leadership role in this area with a large multinational Point-of-Care Testing company. Stephen provides guidance and structure in moving from science to solution, and pre-manufacturing to full production.

“I am pleased to be working with the ChroMedX team, an extremely creative and competent group. I believe that the HemoPalm has some significant technical advances over current devices available in the market and promises to be a significant advancement in Point-of-Care Testing.” said Mr. Cozzette

### **About ChroMedX Corp.**

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.

### **Follow ChroMedX Corp.:**

Website: [www.ChroMedX.com](http://www.ChroMedX.com)

Facebook: [facebook.com/ChroMedXcorp](https://facebook.com/ChroMedXcorp)

Twitter: [www.twitter.com/ChroMedXcorp](https://www.twitter.com/ChroMedXcorp)

### **Investor Enquiries:**

W. Clark Kent  
Corporate Development  
647-519-2646  
[ckent@ChroMedX.com](mailto:ckent@ChroMedX.com)

***NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.***

### **Forward-looking Information Cautionary Statement**

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at [www.sedar.com](http://www.sedar.com)